Vericel (VCEL) Total Current Liabilities (2010 - 2026)
Vericel (VCEL) reported Total Current Liabilities of $47.2 million for Q1 2026, up 19.54% on a YoY basis from $39.4 million in Q1 2025, and down 4.06% sequentially from $49.1 million in Q4 2025.
Vericel (VCEL) Total Current Liabilities (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Total Current Liabilities data on file, last reported at $47.2 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 19.54% year-over-year to $47.2 million; the trailing twelve-month figure through Mar 2026 stood at $47.2 million (up 19.54% YoY), and the FY2025 full-year result was $49.1 million, down 2.26% from the prior year.
- Total Current Liabilities declined to $47.2 million in Q1 2026, from $49.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $50.3 million in Q4 2024 to a low of $21.7 million in Q1 2022.
- A 5-year average of $38.3 million and a median of $39.4 million in 2025 frame the typical range for Total Current Liabilities.
- Peak annual rise in Total Current Liabilities reached 43.8% in 2022, while the deepest fall reached 6.45% in 2022.
- Tracing VCEL's Total Current Liabilities over 5 years: stood at $37.5 million in 2022, then rose by 22.12% to $45.7 million in 2023, then grew by 9.92% to $50.3 million in 2024, then slipped by 2.26% to $49.1 million in 2025, then retreated by 4.06% to $47.2 million in 2026.
- Business Quant data shows VCEL's Total Current Liabilities at $47.2 million in Q1 2026, $49.1 million in Q4 2025, and $45.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 47.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.16 Mn |
| Dec 31, 2025 | 49.15 Mn |
| Sep 30, 2025 | 45.58 Mn |
| Jun 30, 2025 | 41.13 Mn |
| Mar 31, 2025 | 39.45 Mn |
| Dec 31, 2024 | 50.29 Mn |
| Sep 30, 2024 | 41.35 Mn |
| Jun 30, 2024 | 43.86 Mn |
| Mar 31, 2024 | 36.47 Mn |
| Dec 31, 2023 | 45.75 Mn |
| Sep 30, 2023 | 35.95 Mn |
| Jun 30, 2023 | 35.61 Mn |
| Mar 31, 2023 | 28.75 Mn |
| Dec 31, 2022 | 37.46 Mn |
| Sep 30, 2022 | 27.00 Mn |
| Jun 30, 2022 | 25.01 Mn |
| Mar 31, 2022 | 21.73 Mn |
| Dec 31, 2021 | 26.05 Mn |
| Sep 30, 2021 | 18.83 Mn |
| Jun 30, 2021 | 23.86 Mn |